Antiapoptotic Mcl-1 is critical for the survival and niche-filling capacity of Foxp3+ regulatory T cells-Reference-Cited by-同舟云学术

Antiapoptotic Mcl-1 is critical for the survival and niche-filling capacity of Foxp3+ regulatory T cells

Published:2013-07-14 Issue:9 Volume:14 Page:959-965
ISSN:1529-2908
Container-title:Nature Immunology
language:en
Short-container-title:Nat Immunol

Author:

Pierson Wim,Cauwe Bénédicte,Policheni Antonia,Schlenner Susan M,Franckaert Dean,Berges Julien,Humblet-Baron Stephanie,Schönefeldt Susann,Herold Marco J,Hildeman David,Strasser Andreas,Bouillet Philippe,Lu Li-Fan,Matthys Patrick,Freitas Antonio A,Luther Rita J,Weaver Casey T,Dooley James,Gray Daniel H D,Liston Adrian

Publisher

Springer Science and Business Media LLC

Subject

Immunology,Immunology and Allergy

Link

http://www.nature.com/articles/ni.2649.pdf

Reference59 articles.

1. Gavin, M.A. et al. Foxp3-dependent programme of regulatory T-cell differentiation. Nature 445, 771–775 (2007).

2. Sakaguchi, S. et al. FOXP3+ regulatory T cells in the human immune system. Nat. Rev. Immunol. 10, 490–500 (2010).

3. Fontenot, J.D. et al. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat. Immunol. 6, 1142–1151 (2005).

4. Chougnet, C.A. et al. A major role for Bim in regulatory T cell homeostasis. J. Immunol. 186, 156–163 (2011).

5. Siggs, O.M. et al. Opposing functions of the T cell receptor kinase ZAP-70 in immunity and tolerance differentially titrate in response to nucleotide substitutions. Immunity 27, 912–926 (2007).

Cited by 203 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Directed disruption of IL2 aggregation sites produces designer biologics with enhanced specificity coupled to improved production capacity;2024-09-03

2. Increased frequencies of highly activated regulatory T cells skewed to a T helper 1-like phenotype with reduced suppressive capacity in dengue patients;mBio;2024-06-12

3. Interruption of the intratumor CD8+ T cell:Treg crosstalk improves the efficacy of PD-1 immunotherapy;Cancer Cell;2024-06

4. Venetoclax Induces BCL-2–Dependent Treg to TH17 Plasticity to Enhance the Antitumor Efficacy of Anti–PD-1 Checkpoint Blockade;Cancer Immunology Research;2024-05-23

5. Ex vivo characterization of acute myeloid leukemia patients undergoing hypomethylating agents and venetoclax regimen reveals a venetoclax-specific effect on non-suppressive regulatory T cells and bona fide PD-1+TIM3+ exhausted CD8+ T cells;Frontiers in Immunology;2024-05-15